Early pregnancy termination with mifepristone and misoprostol in the United States
BACKGROUND: Mifepristone and a prostaglandin have been used successfully to terminate pregnancy in Europe and China. We report the results of a large U.S. study of mifepristone and misoprostol in women with pregnancies of up to nine weeks' duration.
METHODS: We administered 600 mg of mifepristone and then 400 microg of misoprostol two days later to 2121 women seeking termination of their pregnancies at 17 centers. The women were observed for four hours after the administration of misoprostol and returned on day 15 for final assessment.
RESULTS: Two thousand fifteen women completed the final assessment. Among them, pregnancy was terminated in 762 of the 827 women pregnant for < or =49 days (92 percent), 563 of the 678 women pregnant for 50 to 56 days (83 percent), and 395 of the 510 women pregnant for 57 to 63 days (77 percent) (P<0.001). Termination occurred within 4 hours after the administration of misoprostol in 49 percent of the women and within 24 hours in 75 percent. Failures, defined as cases requiring surgical intervention for medical reasons or because the patient requested it, the abortion was incomplete, or the pregnancy was ongoing, increased with increasing duration of pregnancy. The largest increase was in failures representing ongoing pregnancy, which increased from 1 percent in the < or =49-days group to 9 percent in the 57-to-63-days group (P<0.001). Abdominal pain, nausea, vomiting, diarrhea, and vaginal bleeding also increased with advancing gestational age. Two percent of the women in the < or =49-days group, as compared with 4 percent in each of the other two groups, were hospitalized, underwent surgical interventions, and received intravenous fluids (P=0.008).
CONCLUSIONS: This mifepristone-misoprostol regimen is effective in terminating pregnancies, especially in women with pregnancies of 49 days' duration or less.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1998 |
|---|---|
| Erschienen: |
1998 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:338 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 338(1998), 18 vom: 30. Apr., Seite 1241-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Spitz, I M [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 30.04.1998 Date Revised 21.03.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM095034943 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM095034943 | ||
| 003 | DE-627 | ||
| 005 | 20231222100931.0 | ||
| 007 | tu | ||
| 008 | 231222s1998 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0317.xml |
| 035 | |a (DE-627)NLM095034943 | ||
| 035 | |a (NLM)9562577 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Spitz, I M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early pregnancy termination with mifepristone and misoprostol in the United States |
| 264 | 1 | |c 1998 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 30.04.1998 | ||
| 500 | |a Date Revised 21.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Mifepristone and a prostaglandin have been used successfully to terminate pregnancy in Europe and China. We report the results of a large U.S. study of mifepristone and misoprostol in women with pregnancies of up to nine weeks' duration | ||
| 520 | |a METHODS: We administered 600 mg of mifepristone and then 400 microg of misoprostol two days later to 2121 women seeking termination of their pregnancies at 17 centers. The women were observed for four hours after the administration of misoprostol and returned on day 15 for final assessment | ||
| 520 | |a RESULTS: Two thousand fifteen women completed the final assessment. Among them, pregnancy was terminated in 762 of the 827 women pregnant for < or =49 days (92 percent), 563 of the 678 women pregnant for 50 to 56 days (83 percent), and 395 of the 510 women pregnant for 57 to 63 days (77 percent) (P<0.001). Termination occurred within 4 hours after the administration of misoprostol in 49 percent of the women and within 24 hours in 75 percent. Failures, defined as cases requiring surgical intervention for medical reasons or because the patient requested it, the abortion was incomplete, or the pregnancy was ongoing, increased with increasing duration of pregnancy. The largest increase was in failures representing ongoing pregnancy, which increased from 1 percent in the < or =49-days group to 9 percent in the 57-to-63-days group (P<0.001). Abdominal pain, nausea, vomiting, diarrhea, and vaginal bleeding also increased with advancing gestational age. Two percent of the women in the < or =49-days group, as compared with 4 percent in each of the other two groups, were hospitalized, underwent surgical interventions, and received intravenous fluids (P=0.008) | ||
| 520 | |a CONCLUSIONS: This mifepristone-misoprostol regimen is effective in terminating pregnancies, especially in women with pregnancies of 49 days' duration or less | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Abortifacient Agents | |
| 650 | 4 | |a Abortion, Drug Induced | |
| 650 | 4 | |a Abortion, Induced | |
| 650 | 4 | |a Americas | |
| 650 | 4 | |a Biology | |
| 650 | 4 | |a Developed Countries | |
| 650 | 4 | |a Endocrine System | |
| 650 | 4 | |a Family Planning | |
| 650 | 4 | |a Fertility Control, Postconception | |
| 650 | 4 | |a Hormone Antagonists | |
| 650 | 4 | |a Hormones | |
| 650 | 4 | |a Misoprostol | |
| 650 | 4 | |a North America | |
| 650 | 4 | |a Northern America | |
| 650 | 4 | |a Physiology | |
| 650 | 4 | |a Prostaglandins | |
| 650 | 4 | |a Prostaglandins, Synthetic | |
| 650 | 4 | |a Research Report | |
| 650 | 4 | |a Ru-486 | |
| 650 | 4 | |a United States | |
| 650 | 7 | |a Abortifacient Agents, Nonsteroidal |2 NLM | |
| 650 | 7 | |a Abortifacient Agents, Steroidal |2 NLM | |
| 650 | 7 | |a Receptors, Progesterone |2 NLM | |
| 650 | 7 | |a Misoprostol |2 NLM | |
| 650 | 7 | |a 0E43V0BB57 |2 NLM | |
| 650 | 7 | |a Mifepristone |2 NLM | |
| 650 | 7 | |a 320T6RNW1F |2 NLM | |
| 700 | 1 | |a Bardin, C W |e verfasserin |4 aut | |
| 700 | 1 | |a Benton, L |e verfasserin |4 aut | |
| 700 | 1 | |a Robbins, A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 338(1998), 18 vom: 30. Apr., Seite 1241-7 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:338 |g year:1998 |g number:18 |g day:30 |g month:04 |g pages:1241-7 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 338 |j 1998 |e 18 |b 30 |c 04 |h 1241-7 | ||